Does TAFASITAMAB-CXIX Cause Malignant neoplasm progression? 30 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 30 reports of Malignant neoplasm progression have been filed in association with TAFASITAMAB-CXIX. This represents 4.1% of all adverse event reports for TAFASITAMAB-CXIX.
30
Reports of Malignant neoplasm progression with TAFASITAMAB-CXIX
4.1%
of all TAFASITAMAB-CXIX reports
5
Deaths
3
Hospitalizations
How Dangerous Is Malignant neoplasm progression From TAFASITAMAB-CXIX?
Of the 30 reports, 5 (16.7%) resulted in death, 3 (10.0%) required hospitalization.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TAFASITAMAB-CXIX. However, 30 reports have been filed with the FAERS database.
What Other Side Effects Does TAFASITAMAB-CXIX Cause?
Disease progression (218)
Lymphoma (158)
Off label use (126)
Death (53)
Drug ineffective (39)
Blood lactate dehydrogenase increased (34)
Diffuse large b-cell lymphoma (32)
Neutropenia (30)
Polyneuropathy (29)
Covid-19 (28)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which TAFASITAMAB-CXIX Alternatives Have Lower Malignant neoplasm progression Risk?
TAFASITAMAB-CXIX vs TAFINLAR
TAFASITAMAB-CXIX vs TAFLUPROST
TAFASITAMAB-CXIX vs TAGRAXOFUSP-ERZS
TAFASITAMAB-CXIX vs TAHOR
TAFASITAMAB-CXIX vs TALAZOPARIB